NCT07146217View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions
Bacterial Infections
Interventions
DRUG

Likmez® (metronidazole) Oral Suspension

Each patient will receive 7.5 mg/kg of Likmez® every 6 hours, with a concentration of 100 mg metronidazole/mL

Trial Locations (3)

33155

Bioresearch Partner, Miami

33183

Empire Medical Clinical Trials, Miami

77407

Aavon Clinical Trials, Richmond

Sponsors

Collaborators (1)

CBCC Global Research
All Listed Sponsors
collaborator

CBCC Global Research

NETWORK

lead

Saptalis Pharmaceuticals LLC

INDUSTRY

NCT07146217 - Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection | Biotech Hunter | Biotech Hunter